2086 - Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a Phase 1 study

Background

For pts with unresectable HCC, systemic therapy options are limited. Sorafenib is approved in the US and Europe for HCC treatment. For pts who progress on sorafenib, regorafenib and nivolumab are approved as second-line therapy. Cemiplimab (REGN2810) has demonstrated encouraging efficacy and safety profile in a Phase 1 dose escalation study in pts with advanced malignancies (NCT02383212). We present results of the Phase 1 HCC expansion cohort.

Methods

HCC pts who were not candidates for surgery and had progressed on, could not tolerate, or refused first-line systemic therapy received cemiplimab 3 mg/kg Q2W for up to 48 weeks. The main objectives were to evaluate the safety, tolerability, and antitumour activity of cemiplimab.

Results

As of 1 Sept, 2017, 26 pts were enrolled (25 M/1 F), median (range) age was 65 (40–78) years; 24 pts (92.3%) had ≥1 prior systemic therapy; ECOG performance status was 1 in 19 pts (73.1%), 0 in 6 (23.1%) and missing in 1. Median duration of follow-up was 7.2 (range: 1.8–15.5) months. By investigator assessment, 5 pts (19.2%) had partial response, 14 (53.8%) had stable disease, 6 (23.1%) had progressive disease and 1 was not evaluable. Median progression-free survival was 3.7 months (95% CI: 2.3–9.1). Five pts (19.2%) completed the planned 48-week treatment, and 21 (80.8%) discontinued prematurely, mainly due to disease progression (65.4%). Three of the 5 pts who completed planned treatment remained without disease progression at the last response assessment. The most common treatment-emergent adverse events (TEAEs) of any grade were fatigue (26.9%), decreased appetite, increased aspartate aminotransferase (AST), abdominal pain, pruritus, and dyspnoea (each 23.1%). Grade ≥3 TEAEs occurring in ≥ 2 pts were hyponatraemia (3 pts), autoimmune hepatitis (2 pts) and increased AST (2 pts). Two pts (7.7%) had a TEAE resulting in death: 1 with pulmonary embolism that was considered unrelated to treatment and another with hepatic failure considered possibly related to treatment.

Conclusions

Cemiplimab demonstrated evidence of antitumour activity in pts with advanced or metastatic HCC. The safety profile is comparable with that of other anti-PD-1 inhibitors.

Clinical trial identification

NCT02383212.

Legal entity responsible for the study

Regeneron Pharmaceutical Inc., and Sanofi.

Funding

Regeneron Pharmaceutical Inc. and Sanofi.

Editorial Acknowledgement

Medical writing support under the direction of the authors was provided by Emmanuel Ogunnowo, PhD, of Prime (Knutsford, UK) and funded by Regeneron Pharmaceuticals, Inc. and Sanofi according to Good Publication Practice guidelines (http://annals.org/aim/article/2424869/good-publication-practice-communicating-company-sponsored-medical-research-gpp3).

Disclosure

G.J. Weiss: Personal fees and ownership interest: Circulogene; Ownership interest: Angiex; Personal fees: Paradigm, Igynta, Pfizer, Merck, Idea Pharma, GLG Council, Novartis; Travel/lodging fees: Cambridge Healthtech Institute, Tesaro, and Nantworks; Patent PCT/US2011/020612 issued. G.S. Falchook: Funding for trial for submitted work. N. Yee: Research, travel, accommodation and expenses: Daiichi Sankyo, Foundation Medicine and Caris Life Sciences. S. Shahda: Advisory board fees: Ipsen and Bayer; Research grants: Incyte and Apexian. M. Crittenden: Research funding: Jounce and Nanobiotix. R. Al-Rajabi: Grants: Regeneron Pharmaceuticals, Inc. E. Stankevich: Shareholder and employee: Regeneron Pharmaceuticals, Inc., Shareholder: Celgene, Bristol-Myers Squibb, and Merck. M. Feng: Shareholder and employee: Regeneron Pharmaceuticals, Inc., Shareholder: Bayer. J. Li, M. Mathias, G. Kroog: Shareholder and employee: Regeneron Pharmaceuticals, Inc. I. Lowy: Shareholder and employee, fees for travel and accommodation expenses, leadership: Regeneron Pharmaceuticals, Inc. M.G. Fury: Shareholder, employee, holds patents, royalties, other intellectual property: Regeneron Pharmaceuticals, Inc. All other authors have declared no conflicts of interest.